Roche: priority review for drug Perjeta.
(CercleFinance.com) - Roche has announced that the US FDA has granted priority review for its Perjeta (pertuzumab), in combination with Herceptin and chemotherapy, for adjuvant treatment (after surgery) of HER2-positive early breast cancer.
This additional biological product license application is based on the results of the Aphinity Phase III study. Health authorities in the US will make their final decision on approval by 28 January 2018.
“A Priority Review designation is granted to medicines that the FDA has determined to have the potential to provide significant improvements in the treatment, prevention or diagnosis of a disease” the Swiss health group said.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
This additional biological product license application is based on the results of the Aphinity Phase III study. Health authorities in the US will make their final decision on approval by 28 January 2018.
“A Priority Review designation is granted to medicines that the FDA has determined to have the potential to provide significant improvements in the treatment, prevention or diagnosis of a disease” the Swiss health group said.
Copyright (c) 2017 CercleFinance.com. All rights reserved.